Page 1

Source : Amphastar Pharmaceuticals , Inc. May 06 , 2021 16:05 ET Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31 , 2021 Reports Net Revenues of $ 103.0 Million for the Three Months Ended March 31 , 2021 RANCHO CUCAMONGA , Calif . , May 06 , 2021 ( GLOBE NEWSWIRE ) -- Amphastar Pharmaceuticals , Inc. ( NASDAQ : AMPH ) ( “ Amphastar ” or the “ Company ” ) today reported results for the three months ended March 31 , 2021 . First Quarter Highlights • Net revenues of $ 103.0 million for the first quarter . GAAP net income of $ 5.0 million , or $ 0.10 per share , for the first quarter • Adjusted non - GAAP net income of $ 13.6 million , or $ 0.27 per share , for the first quarter Dr. Jack Zhang , Amphastar's President and Chief Executive Officer commented : “ The launch of glucagon , along with strong sales growth of Primatene MistⓇ and our epinephrine products , contributed to one of Amphastar's strongest quarters in terms of sales growth to date . We expect that these core growth products will continue to drive growth for the remainder of the year , while we are confident in seeing our pipeline develop to diversify our portfolio . " Net revenues GAAP net income attributable to Amphastar Adjusted non - GAAP net income attributable to Amphastar * GAAP diluted EPS attributable to Amphastar stockholders Adjusted non - GAAP diluted EPS attributable to Amphastar stockholders * Three Months Ended March 31 , 2021 2020 ( in thousands , except per share data ) SSS A $ 103,020 $ 84,688 $ 5,041 $ 3,949 13,553 $ 8,383 $ 0.10 $ 0.08 0.27 $ 0.17 * Adjusted non - GAAP net income and Adjusted non - GAAP diluted EPS are non - GAAP financial measures . Please see the discussion in the section entitled " Non - GAAP Financial Measures " and the reconciliation of GAAP to non - GAAP financial measures in Table III of this press release . First Quarter Results Three Months Ended March 31 , Change 2021 2020 ( in thousands ) Dollars % Net revenues : Primatene MistⓇ Epinephrine Enoxaparin Phytonadione $ 18,383 $ 12,877 $ 5,506 43 % 15,578 10,658 9,168 3,990 11,588 1,490 290 % 16 % 9,565 11,029 ( 1,464 ) ( 13 ) % Lidocaine 9,071 10,657 ( 1,586 ) ( 15 ) % Glucagon 7,984 7,984 ΝΙΑ Naloxone 6,341 8,875 ( 2,534 ) ( 29 ) % Other finished pharmaceutical products 20,302 24,702 ( 4,400 ) ( 18 ) %